Yashaswi Shrestha

7PUBLICATIONS
44CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMechanobiologyProgramming languagesImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 17, 2024
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study.

Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski

|Oct 06, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.

Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen

|Jul 07, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

Nabendu Pore, Song Wu, Nathan Standifer

|Sep 23, 2020
IL-33-ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regeneration.

Rania Dagher, Alan M Copenhaver, Valerie Besnard

|Nov 15, 2019
Author Correction: c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies.

Jochem H Bernink, Yoichiro Ohne, Marcel B M Teunissen

|Jul 03, 2019
c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies.

Jochem H Bernink, Yoichiro Ohne, Marcel B M Teunissen

Pageof 2

Frequent Collaborators

3 joint publications

Alison A Humbles

2 joint publications

Rajiv Raja

2 joint publications

Marcel B M Teunissen

2 joint publications

Christine Guntermann